The headline reads like a breakthrough for anyone with herpes. The label says something far narrower. On October 9, the US Food and Drug Administration approved pritelivir, sold as Hovilpri, for immunocompromised adults whose herpes simplex virus (HSV) lesions on the skin or mucous membranes have not responded to acyclovir, valacyclovir or famciclovir. It is not a cold-sore pill. It is a rescue drug for people whose standard options have run out.

A first in nearly three decades

Asahi Kasei Therapeutics, which announced the approval, called it the first FDA-approved HSV therapy with a novel mechanism of action in nearly 30 years, according to a company statement carried by Reuters. Pritelivir is a helicase-primase inhibitor. Older drugs such as acyclovir block the viral DNA polymerase. Pritelivir targets a different set of viral proteins that the virus needs to copy its genome, so it should still work against strains that have learned to evade the old drugs, the Pharmacy Times explained.

The molecule has a European origin. It was developed by AiCuris, a German anti-infectives company that Asahi Kasei, a Japanese group, finished acquiring in April 2026, per RegulatoryNews. The FDA granted Fast Track, Breakthrough Therapy and Priority Review designations along the way. The company expects the drug to reach US patients before the end of 2026.

Why the old drugs fail where they matter most

For most people, HSV is a nuisance. For transplant recipients and people with blood cancers or advanced HIV, it can become relentless. The Centers for Disease Control and Prevention notes that acyclovir-resistant strains are also resistant to valacyclovir, and most are resistant to famciclovir, because they share a pathway. CDC guidance then points to intravenous foscarnet.

That fallback carries its own harm. A multicenter retrospective study of foscarnet, cited by Pharmacy Times, covered 31 treatment episodes in immunocompromised adults. Only 15 resolved during or after therapy. Electrolyte disturbances occurred in 65 percent of episodes, kidney dysfunction in 42 percent, and side effects led to stopping the drug in 32 percent. That is observational data and not a head-to-head comparison with pritelivir, but it shows what clinicians have been working with.

What the trial showed

The approval rests on Part C of PRIOH-1, a phase 3 randomized trial of 101 immunocompromised adults with refractory mucocutaneous HSV infection. Participants had hematologic cancers, stem-cell or solid-organ transplants, HIV, or autoimmune and inflammatory conditions. They received pritelivir, 100 mg daily, or investigator-selected treatment for up to 28 days, with extension to 42 days for those who were improving. Comparators included foscarnet, cidofovir and imiquimod, according to Contemporary OB/GYN.

Complete healing of all lesions by day 28 occurred in 63 percent of patients on pritelivir and 34 percent on the alternatives. The manufacturer reported an adjusted difference of 28.4 percentage points, with a 95 percent confidence interval of 9.6 to 47.3 and a P value of .0047.

Read that interval carefully. The lower bound is under 10 points and the upper bound is nearly 50. With 101 patients, the trial establishes that the drug probably works better than the alternatives, but not by exactly how much.

What the numbers cannot tell us

Pharmacy Times pointed to several limits. The trial was open-label, so patients and doctors knew who was getting what. The comparator was whatever the investigator chose, which varied. The endpoint was lesion healing, not elimination of the virus, since HSV is a lifelong infection that these drugs suppress rather than cure. And the results apply only to the studied group: immunocompromised adults with refractory mucocutaneous disease. They say nothing about healthy people with recurrent genital herpes or cold sores.

The PRIOH-1 study was supported by AiCuris, as Medscape noted. That is normal for drug trials and not a reason to doubt the result, but it is a reason to wait for independent follow-up. The same pattern, a clear benefit on a defined endpoint with open questions beyond it, shows up in the FDA's approval of Tecentriq for Stage III colon cancer a day earlier, where overall survival has not yet been shown to differ.

The practical catches

Headache was the most common adverse reaction the FDA identified, according to Pharmacy Times. The more important issue is interactions. Certain acid-reducing medicines can lower pritelivir exposure and weaken its effect. The manufacturer advises avoiding some proton pump inhibitor regimens, taking pritelivir at least two hours before or 12 hours after H2-receptor blockers, and at least two hours before or after antacids. Pritelivir also inhibits a transporter called breast cancer resistance protein, which can raise levels of drugs that depend on it.

That matters because the patients most likely to need pritelivir are often on long medication lists. Acid suppression is common after transplant and chemotherapy. A drug that works well in a trial but loses effect because of a routine stomach pill would be a hard way to learn the lesson.

One company estimate, reported by RegulatoryNews, puts the US population who could be eligible at roughly 15,000 people. That is small, which fits the pattern for new antivirals: the first approval often arrives for the group with the fewest alternatives. Whether pritelivir moves earlier in treatment, or reaches people with milder disease, will depend on trials that have not been run yet.

For now, the value of this approval is not breadth but proof. After nearly three decades without a new mechanism, resistant herpes in the most vulnerable patients finally has a treatment that does not depend on the pathway the virus already knows how to escape.

---